




ASPECT READER™

- RFID for automatic upload of lot specific information
- Factory calibrated
- Internal reader check on every initialization
- QC lockout
- LIS connectivity
- Built-in printer

ASPECT-PLUS™ ST2 TEST

- CV: 14.2%* **
- Analytical Sensitivity: 12.5 ng/ml*
- Linear up to 257 ng/mL
- Sample: 35 µL EDTA plasma
- Integrated Quality Control with each test cassette
- RFID with each test cassette containing lot specific information
- Single cutpoint: 35ng/mL

Revealing a Unique ASPECT of Heart Failure



*ASPECT-PLUS Instructions For Use.

**CV is TOTAL CV at 32 ng/mL.

1. Ky B, et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation Heart Fail. 201
2. Snider, J, et al. Heart Failure Congress, 2012. A677.

ASPECT-PLUS and ASPECT Reader are CE marked, and not available for sale in the United States.

CRITICAL
DIAGNOSTICS

© Copyright. 2014 Critical Diagnostics.

3030 Bunker Hill Street, Suite 117A
San Diego, CA 92109
Telephone: +1 877 700 1250
Fax: +1 866 715 8009
criticaldiagnostics.com


AW201163 Rev.1

FOR USE OUTSIDE OF UNITED STATES ONLY

 Aspect-PLUS™
ST2 Rapid Test


RAPID.

THE ONLY RAPID ST2 TEST.



INITIATE TEST

20 minutes



ST2 RESULT


HF STATUS.

ST2 LEVEL REFLECTIVE OF CLINICAL STATUS.



Cardiac remodeling and fibrosis are not easily detectable until the patient is symptomatic.

An elevated ST2 level is predictive of disease progression that is not reflected by existing tests. ST2 reclassifies 15% of patients to more appropriate risk categories¹, and when used with natriuretic peptides risk prediction improves nearly 5X when both are elevated¹.



CUSTOMIZED CARE.

EVERY PATIENT IS DIFFERENT.




ST2 levels change quickly, distinctively highlighting severity of HF and response to current treatment.

A change in ST2 level to below 35 ng/mL that may benefit from a customized care plan that lowers their risk for morbidity, mortality, or rehospitalization.

A change in ST2 level below 35 ng/mL is prognostic of favorable outcomes for those patients that may not be identifiable with traditional tools.

ST2 CHANGE PREDICT OUTCOMES²



Serial testing of ST2 adds value. For example, patients whose ST2 level is high but drops to low, tend to do as well as those who are low and stay low.

LOWER RISK

Patient is at lower risk. Manage patient according to standard care consistent with clinical evaluation.

35

ng/mL

HIGH RISK

Patient is at HIGH risk. Aggressive management according to guidelines.